Prosztatarák: vizsgálatok itt: Kanada
129 trials · From ClinicalTrials.gov, checked 2026. november 11.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - 2. fázisTaking peopleA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00 - 3. fázisTaking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Edmonton, Greenfield Park, Montreal, Ottawa, Québec, Sherbrooke, Toronto
- Életkor
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - 1. fázisTaking peopleA Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Where
- Hamilton, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 421 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07114601 · EU 2025-522367-15-00 - 2. fázisNot yet taking people in KanadaPSMA-PET Directed Radiation Therapy for High-Risk Prostate Cancer
- Where
- Edmonton
- Életkor
- 18 év and over
- People
- 250
- Run by
- AHS Cancer Control Alberta
See details and how to joinNCT07291557 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Where
- Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT05800665 · EU 2023-504013-68-00 - 3. fázisTaking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Calgary, Oshawa, Québec, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 1203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - 3. fázisTaking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Montreal, Ottawa, Québec, Toronto, Vancouver, Victoria
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - 3. fázisTaking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Calgary, Chicoutimi, Edmonton, Halifax, Montreal, Oshawa
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - No phaseTaking peopleMainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic Testing
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 180
- Run by
- Unity Health Toronto
See details and how to joinNCT07387263 - 1/2. fázisTaking peopleStudy of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 205 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07288359 - 2. fázisNot yet taking people in KanadaAdaptive Radiotherapy for Safe Hypofractionation
- Where
- Montreal
- People
- 264
- Run by
- Centre hospitalier de l'Université de Montréal (CHUM)
See details and how to joinNCT07516210 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Edmonton, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 3. fázisTaking peopleTesting Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
- Where
- Montreal, Ottawa, Québec, Saint John, Sherbrooke, Toronto
- Életkor
- 18 év and over
- People
- 1500 worldwide
- Run by
- NRG Oncology
See details and how to joinNCT05946213 - 1. fázisTaking peopleA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Where
- Montreal, Toronto
- Életkor
- 18 év and over
- People
- 208 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07570979 - 2. fázisTaking peopleClinical Trial to Observe the Effects of Tamoxifen on Testosterone Recovery in Medically Castrated Prostate Cancer Patients
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 96
- Run by
- University Health Network, Toronto
See details and how to joinNCT07535905 - 3. fázisTaking peopleAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
- Where
- Calgary, Halifax, London, Montreal, Ottawa, Québec, Toronto
- Életkor
- 18 év to 100 év
- People
- 450 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT05939414 · EU 2022-502956-29-00 - 3. fázisTaking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Abbotsford British Columbia, Edmonton, Mississauga, Montreal, Ottawa, Québec, Toronto
- Életkor
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - No phaseTaking peopleSalvage MR-guided High-Dose-Rate Brachytherapy for Prostate Bed Recurrence After Radiotherapy in the PSMA PET Scan Era
- Where
- Toronto
- Életkor
- 18 év and over
- People
- 20
- Run by
- University Health Network, Toronto
See details and how to joinNCT06508567 - 3. fázisTaking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Montreal, Sherbrooke, Toronto
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - 3. fázisTaking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Edmonton, Halifax, Hamilton, Montreal, Toronto
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 3. fázisTaking peopleSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Abbotsford British Columbia, Brampton, Calgary, Edmonton, Greenfield Park, Kitchener, Montreal, North York, Ottawa, Saint-Jérôme, Saskatoon, Toronto, Windsor
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00 - 3. fázisTaking peopleA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
- Where
- Abbotsford British Columbia, Barrie, Brampton, Calgary, Chicoutimi, London, Montreal, Saskatoon, Toronto, Vancouver
- Életkor
- 18 év and over
- People
- 700 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT06952803 · EU 2024-513586-39-00 - 3. fázisTaking peopleThis Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
- Where
- Calgary, Greenfield Park, Halifax, Montreal, Québec, Sherbrooke, Trois-Rivières
- Életkor
- 18 év and over
- People
- 1000 worldwide
- Run by
- Pfizer
See details and how to joinNCT07028853 · EU 2024-519369-24-00 - 2. fázisTaking peopleStudy of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
- Where
- Hamilton, Montreal, Ottawa, Toronto
- Életkor
- 18 év and over
- People
- 162
- Run by
- Ontario Clinical Oncology Group (OCOG)
See details and how to joinNCT06654336